Skip to content
Austin Top 50
Author:
Biosplice Therapeutics, Inc.
European Medicines Agency Validates Biosplice’s Application for Lorecivivint (LOR) in Knee Osteoarthritis and Begins Review
October 2, 2026
Lorecivivint for Knee OA: UK MHRA Accepts Biosplice Application
September 8, 2026